The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

Its lead candidates treat solid tumors, non-small cell lung cancer (NSCLC) and brain metastases. The company works in collaboration with contract research organizations (CROs), medical institutions ...

Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Getting a diagnosis of lung cancer can be scary, especially when you don't know what to expect. To help, experts will guide ...